Search Results for: stem cells for MS

Weekly reads: oocytes from males, David Sinclair longevity inc, diabetes, He Jiankui

David Sinclair

A team led by Harvard professor David Sinclair had a recent Cell paper on reprogramming to fight aging that I reviewed here on The Niche. I thought the paper was exciting and important. Note that in vivo reprogramming was first done more than a decade ago. Sinclair did have a novel fast-forward aging method and overall […]

Weekly reads: oocytes from males, David Sinclair longevity inc, diabetes, He Jiankui Read More »

Where Kimera Labs fits into sphere of exosome companies

Kimera labs exosome

Today’s post takes a close look at the exosome manufacturer Kimera Labs in the context of the main exosome companies. What are exosomes? Exosomes are microscopic bubbles or vesicles produced by cells. Exosomes contain many cellular substances that are biologically active. Some of these materials may be helpful clinically, while others could pose risks. Clinical outcomes

Where Kimera Labs fits into sphere of exosome companies Read More »

Weekly reads: human CRISPR, MRT risks, private IRBs, skincare

David Liu, human CRISPR

It’s funny how sometimes there are many new articles about one general topic like this week with heritable (and somatic) human CRISPR gene editing and related tech.  There are clear reasons for optimism in the somatic arena given advancing trials. Germline editing remains highly questionable in my view even just technically. Then there are loads

Weekly reads: human CRISPR, MRT risks, private IRBs, skincare Read More »

Does NurOwn from BrainStorm Cell Therapeutics still provide hope for ALS?

Chaim Lebovits, CEO of BrainStorm Cell Therapeutics.

What is the cell therapy for ALS called NurOwn? How strong is its potential as a treatment for ALS? I’ve been following the biotech BrainStorm Cell Therapeutics for many years. Patients keep asking me about NurOwn ALS prospects. They’re looking for hope. Today’s post is a close look at NurOwn and at BrainStorm as a

Does NurOwn from BrainStorm Cell Therapeutics still provide hope for ALS? Read More »

Weekly reads: He Jiankui disappoints, ALS, Vor Biopharma

He Jiankui

I’m sure many of you remember He Jiankui, the guy who made CRISPR babies. He ended up serving three years in jail in China. He seems to be trying for something of a comeback since his release. Were He Jiankui invitations a mistake? Some prestigious places have even invited him to give talks, which seemed

Weekly reads: He Jiankui disappoints, ALS, Vor Biopharma Read More »

Perspectives on David Sinclair anti-aging Cell pub & in vivo reprogramming

methuselah mouse, anti-aging

About twenty years ago a science story made big news of a so-called anti-aging Methuselah gene. Methuselah gene and anti-aging The claim was that this DNA conferred long life on people. Hence the name Methuselah, which refers to a man from the Bible who reportedly lived 969 years. The so-called Methuselah gene was at first not a

Perspectives on David Sinclair anti-aging Cell pub & in vivo reprogramming Read More »

Skepticism on the Bryan Johnson anti-aging extravaganza

Oliver Zolman, Bryan Johnson

Near-billionaire Bryan Johnson apparently does not like getting old and he’s trying to do something transformative about it. He and his team are experimenting in a big way.  As a 55-year-old myself, I can’t blame him for wanting to fight aging in general. However, his anti-aging project includes some extreme stuff. Will some in the

Skepticism on the Bryan Johnson anti-aging extravaganza Read More »

Weekly reads: reprogramming aging, astrocytes, cartilage, ChatGPT

Let’s start with a couple of new pieces on in vivo reprogramming. The idea here is to do something like making iPS cells but doing it inside organisms and not quite pushing cells all the way back to pluripotency. Just younger, healthier cells. Why do that? The goal is to achieve a kind of anti-aging

Weekly reads: reprogramming aging, astrocytes, cartilage, ChatGPT Read More »